STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 95 filers reported holding STOKE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,969 | -62.9% | 1,515 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $16,104 | +53.4% | 1,515 | +20.2% | 0.00% | 0.0% |
| Q1 2023 | $10,496 | -18.9% | 1,260 | -10.1% | 0.00% | 0.0% |
| Q4 2022 | $12,940 | -23.9% | 1,402 | +5.8% | 0.00% | 0.0% |
| Q3 2022 | $17,013 | -2.8% | 1,325 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $17,503 | -37.2% | 1,325 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $27,891 | -79.3% | 1,325 | -76.4% | 0.00% | -50.0% |
| Q4 2021 | $134,680 | -5.7% | 5,614 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $142,820 | -24.4% | 5,614 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $188,967 | +28.7% | 5,614 | +48.5% | 0.00% | +50.0% |
| Q1 2021 | $146,815 | -37.3% | 3,780 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $234,095 | +84.9% | 3,780 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $126,592 | -3.9% | 3,780 | -31.6% | 0.00% | 0.0% |
| Q2 2020 | $131,661 | +4.1% | 5,525 | 0.0% | 0.00% | -33.3% |
| Q1 2020 | $126,523 | +31.2% | 5,525 | +62.3% | 0.00% | +50.0% |
| Q4 2019 | $96,430 | – | 3,405 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 14,443,681 | $56,908,103 | 99.78% |
| Lynx1 Capital Management LP | 1,710,154 | $6,738,007 | 4.46% |
| COWEN AND COMPANY, LLC | 3,721,659 | $14,663,336 | 1.03% |
| Redmile Group, LLC | 3,872,696 | $15,258,422 | 0.73% |
| RTW INVESTMENTS, LP | 4,390,558 | $17,298,799 | 0.36% |
| Birchview Capital, LP | 85,000 | $334,900 | 0.28% |
| Cormorant Asset Management, LP | 1,087,807 | $4,285,960 | 0.25% |
| Granahan Investment Management | 851,201 | $3,353,732 | 0.12% |
| GSA CAPITAL PARTNERS LLP | 348,069 | $1,371 | 0.12% |
| Simplify Asset Management Inc. | 102,985 | $405,761 | 0.05% |